Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1991 2
1992 1
1995 1
2002 2
2003 2
2004 5
2005 3
2006 7
2007 4
2008 3
2009 8
2010 8
2011 14
2012 33
2013 18
2014 25
2015 56
2016 48
2017 39
2018 34
2019 13
2020 18
2021 10
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

349 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group. Baeten D, et al. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066. N Engl J Med. 2015. PMID: 26699169 Free article. Clinical Trial.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T, Kaul M, Szántó A, Tseng JC, Papas AS, Pylvaenaeinen I, Hanser M, Abdallah N, Grioni A, Santos Da Costa A, Ferrero E, Gergely P, Hillenbrand R, Avrameas A, Cenni B, Siegel RM. Dörner T, et al. Among authors: tseng jc. Ann Rheum Dis. 2024 Feb 15;83(3):360-371. doi: 10.1136/ard-2023-224691. Ann Rheum Dis. 2024. PMID: 37932009 Free PMC article. Clinical Trial.
Patient with abnormal eye movement.
Cheng TH, Chao HY, Tseng JC, Chen HY. Cheng TH, et al. Among authors: tseng jc. J Am Coll Emerg Physicians Open. 2022 Jul 15;3(4):e12789. doi: 10.1002/emp2.12789. eCollection 2022 Aug. J Am Coll Emerg Physicians Open. 2022. PMID: 35859858 Free PMC article. No abstract available.
Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis.
Wei JC, Liu CH, Tseng JC, Hsieh LF, Chen CH, Chen HH, Chen HA, Chen YC, Chou CT, Liao HT, Lin YC, Luo SF, Yang DH, Yeo KJ, Tsai WC; Taiwan Rheumatology Association (TRA). Wei JC, et al. Among authors: tseng jc. Int J Rheum Dis. 2020 Jan;23(1):7-23. doi: 10.1111/1756-185X.13752. Epub 2019 Nov 27. Int J Rheum Dis. 2020. PMID: 31777200 Free PMC article. Review.
349 results